NasdaqGM - Delayed Quote USD

ABIVAX Société Anonyme (ABVX)

Compare
6.38
-0.30
(-4.49%)
At close: 4:00:01 PM EST
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
--
--
50,764.00
45,517.00
33,783.00
Gross Profit
--
--
-50,764.00
-45,517.00
-33,783.00
Operating Expense
127,376.00
127,376.00
51,205.00
41,398.00
4,226.00
Operating Income
-127,376.00
-127,376.00
-51,205.00
-41,398.00
-38,009.00
Net Non Operating Interest Income Expense
-12,708.00
-12,708.00
-6,717.00
-3,476.00
-2,318.00
Other Income Expense
-7,654.00
-7,654.00
-2,820.00
2,425.00
200.00
Pretax Income
-147,740.00
-147,740.00
-60,740.00
-42,452.00
-40,127.00
Tax Provision
--
--
--
--
-2,575.00
Net Income Common Stockholders
-147,740.00
-147,740.00
-60,740.00
-42,452.00
-37,551.00
Diluted NI Available to Com Stockholders
-147,740.00
-147,740.00
-60,740.00
-42,452.00
-37,551.00
Basic EPS
-3.43
-3.43
-3.18
-2.75
-2.62
Diluted EPS
-3.43
-3.43
-3.18
-2.75
-2.62
Basic Average Shares
43,066.01
43,066.01
19,092.44
15,455.99
14,332.44
Diluted Average Shares
43,066.01
43,066.01
19,092.44
15,455.99
14,332.44
Total Operating Income as Reported
-127,376.00
-127,376.00
-64,836.00
-41,400.00
-38,008.00
Rent Expense Supplemental
482.00
--
1,048.00
548.00
504.00
Total Expenses
127,376.00
127,376.00
51,205.00
41,398.00
38,009.00
Net Income from Continuing & Discontinued Operation
-147,740.00
-147,740.00
-60,740.00
-42,452.00
-37,551.00
Normalized Income
-136,888.00
-136,888.00
-56,474.00
-44,877.00
-37,738.17
Interest Income
2,773.00
2,773.00
--
--
--
Interest Expense
13,826.00
13,826.00
6,940.00
3,558.00
2,062.00
Net Interest Income
-12,708.00
-12,708.00
-6,717.00
-3,476.00
-2,318.00
EBIT
-133,914.00
-133,914.00
-53,800.00
-38,894.00
-38,065.00
EBITDA
-133,207.00
-133,207.00
-53,315.00
-38,592.00
-37,999.00
Reconciled Cost of Revenue
--
--
50,526.00
45,517.00
33,783.00
Reconciled Depreciation
707.00
707.00
485.00
302.00
66.00
Net Income from Continuing Operation Net Minority Interest
-147,740.00
-147,740.00
-60,740.00
-42,452.00
-37,551.00
Total Unusual Items Excluding Goodwill
-10,852.00
-10,852.00
-4,266.00
2,425.00
200.00
Total Unusual Items
-10,852.00
-10,852.00
-4,266.00
2,425.00
200.00
Normalized EBITDA
-122,355.00
-122,355.00
-49,049.00
-41,017.00
-38,199.00
Tax Rate for Calcs
--
--
--
--
0.00
Tax Effect of Unusual Items
--
--
--
--
12.83
12/31/2020 - 10/20/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SYRE Spyre Therapeutics, Inc.
22.46
-6.49%
 
MEDCL.PA MedinCell S.A.
16.48
-2.25%
 
MLTX MoonLake Immunotherapeutics
46.32
-3.85%
 
ELVN Enliven Therapeutics, Inc.
21.74
-9.98%
 
PHVS Pharvaris N.V.
17.80
-3.99%
 
ANAB AnaptysBio, Inc.
14.21
-1.04%
 
AVTE Aerovate Therapeutics, Inc.
2.5500
-3.41%
 
RAPP Rapport Therapeutics, Inc.
14.81
-11.26%
 
BIOA-B.ST BioArctic AB (publ)
206.80
+1.08%
 
I54.F Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
0.8150
+3.16%